XML 48 R38.htm IDEA: XBRL DOCUMENT v3.25.0.1
Accrued Expenses and Other Liabilities (Tables)
12 Months Ended
Dec. 31, 2024
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses and Other Liabilities

Accrued expenses and other liabilities consist of the following as of December 31 (in thousands):

 

 

2024

 

 

2023

 

Accrued preclinical and clinical trial expenses

 

$

267

 

 

$

1,015

 

Accrued professional fees

 

 

11,011

 

 

 

4,730

 

Accrued compensation and benefits

 

 

10,746

 

 

 

8,883

 

Accrued license fees

 

 

30,991

 

 

 

24,437

 

Accrued purchases

 

 

447

 

 

 

192

 

Operating lease liability

 

 

402

 

 

 

369

 

Accrued gross-to-net revenue liabilities*

 

 

44,939

 

 

 

6,877

 

Accrued income tax

 

 

894

 

 

 

729

 

Due to licensor

 

 

3,582

 

 

 

12,540

 

Accrued interest payable

 

 

389

 

 

 

1,031

 

Other

 

 

417

 

 

 

465

 

Current accrued expenses and other liabilities

 

 

104,085

 

 

 

61,268

 

Lease liability – non-current

 

 

2,786

 

 

 

3,188

 

Due to licensor – non-current

 

 

 

 

 

2,497

 

Other – non-current

 

 

315

 

 

 

485

 

Non-current accrued expenses and other liabilities

 

 

3,101

 

 

 

6,170

 

Total accrued expenses and other liabilities

 

$

107,186

 

 

$

67,438

 

 

* During 2023, the Company sold FYCOMPA® through a Transition Service Agreement with Eisai. Effective January 1, 2024, FYCOMPA® is being sold and distributed through a 3PL organization under the Company's contracts.